LCP
BMRN icon

Lamond Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lamond Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$10.5M – 10
2015
Q3 		$10.5M Buy
+100,000
New +$13.4M 7.88% 8
2015
Q1 		– Sell
-91,840
Closed -$8.3M – 14
2014
Q4 		$8.3M Buy
+91,840
New +$7.64M 5.44% 9

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lamond Capital Partners's BMRN Position: Q4 2015 in Review

Lamond Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 100,000 shares — an estimated $10.5M sold.

Lamond Capital Partners first reported a position in BMRN in Q4 2014 and held it in 2 quarters. The position peaked at $10.5M in Q3 2015. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

  • Lamond Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 100,000 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $10.5M.
  • Lamond Capital Partners first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Lamond Capital Partners's BioMarin Pharmaceuticals position peaked at $10.5M in Q3 2015.
  • 388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Lamond Capital Partners's 13F filing for Q4 2015, filed 9 Feb 2016.